Imavec/Imavec 400 100 mg, 400 mg CAPSULES
PDF Leaflet Revision Date: 18 August 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including CML and GIST.
Dosage (summary)
400 mg daily for chronic phase CML; 600 mg for accelerated phase; 800 mg for DFSP.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Not established; contraindicated in pregnancy and lactation.
Key Drug Interactions
- CYP3A4 inducers (e.g., rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole)
- Warfarin
Contraindications
- Hypersensitivity to imatinib
- Pregnancy
- Lactation
Common side effects
- Fluid retention
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
Counselling Points
- Monitor for signs of liver dysfunction
- Avoid grapefruit juice
- Use effective contraception during treatment
Serious warnings
- Hepatitis B reactivation
- Cerebrovascular events
- Severe fluid retention
Important Disclaimer
The Imavec/Imavec 400 100 mg, 400 mg CAPSULES professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
